Literature DB >> 17088474

Calcific aortic stenosis: a disease ready for prime time.

Nalini M Rajamannan.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 17088474      PMCID： PMC3951842          DOI： 10.1161/CIRCULATIONAHA.106.657759

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  26 in total

Review 1.  Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both?

Authors:  D E Newby; S J Cowell; N A Boon
Journal:  Heart       Date:  2006-06       Impact factor: 5.994

2.  Experimental aortic valve stenosis in rabbits.

Authors:  Marie-Claude Drolet; Marie Arsenault; Jacques Couet
Journal:  J Am Coll Cardiol       Date:  2003-04-02       Impact factor: 24.094

3.  A cytochemical study of the surface properties of aortic and mitral valve endothelium from hypercholesterolemic rabbits.

Authors:  T G Sarphie
Journal:  Exp Mol Pathol       Date:  1986-06       Impact factor: 3.362

4.  Calcific aortic stenosis: medical and surgical management in the elderly.

Authors:  Nalini M Rajamannan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-12

5.  Bone formation and inflammation in cardiac valves.

Authors:  E R Mohler; F Gannon; C Reynolds; R Zimmerman; M G Keane; F S Kaplan
Journal:  Circulation       Date:  2001-03-20       Impact factor: 29.690

6.  Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals.

Authors:  Jian-Su Shao; Su-Li Cheng; Joyce M Pingsterhaus; Nichole Charlton-Kachigian; Arleen P Loewy; Dwight A Towler
Journal:  J Clin Invest       Date:  2005-04-14       Impact factor: 14.808

7.  Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves.

Authors:  M Olsson; J Thyberg; J Nilsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-05       Impact factor: 8.311

8.  Distribution of SPARC during neovascularisation of degenerative aortic stenosis.

Authors:  A Charest; A Pépin; R Shetty; C Côté; P Voisine; F Dagenais; P Pibarot; P Mathieu
Journal:  Heart       Date:  2006-05-18       Impact factor: 5.994

9.  Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve.

Authors:  N M Rajamannan; M Subramaniam; S R Stock; N J Stone; M Springett; K I Ignatiev; J P McConnell; R J Singh; R O Bonow; T C Spelsberg
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

10.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis.

Authors:  K D O'Brien; D D Reichenbach; S M Marcovina; J Kuusisto; C E Alpers; C M Otto
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-04       Impact factor: 8.311
View more
  16 in total

1.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

Review 2.  Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification.

Authors:  Sophie E P New; Elena Aikawa
Journal:  Circ Res       Date:  2011-05-27       Impact factor: 17.367

3.  Rac1 mediates cadherin-11 induced cellular pathogenic processes in aortic valve calcification.

Authors:  Kiran A Vaidya; Matthew P Donnelly; Ablajan Mahmut; Jae Woong Jang; Terence W Gee; Marine-Ayan Ibrahim Aibo; Robert Bossong; Clare Hall; Sanjay Samb; Jonathan Chen; Jonathan T Butcher
Journal:  Cardiovasc Pathol       Date:  2022-01-21       Impact factor: 2.185

4.  [The "asymptomatic" patient with chronic acquired heart valve disease].

Authors:  D Horstkotte; C Prinz; C Piper
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

5.  Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix.

Authors:  Edward B Neufeld; Leah M Zadrozny; Darci Phillips; Angel Aponte; Zu-Xi Yu; Robert S Balaban
Journal:  Atherosclerosis       Date:  2014-01-08       Impact factor: 5.162

6.  Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice.

Authors:  Cordelia J Barrick; Reade B Roberts; Mauricio Rojas; Nalini M Rajamannan; Carolyn B Suitt; Kevin D O'Brien; Susan S Smyth; David W Threadgill
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-15       Impact factor: 4.733

7.  Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction.

Authors:  Bin Liu; Tonghong Xu; Xinning Xu; Yuzhu Cui; Xiaojing Xing
Journal:  Mol Cell Biochem       Date:  2018-05-14       Impact factor: 3.396

8.  Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2.

Authors:  Rui Song; Qingchun Zeng; Lihua Ao; Jessica A Yu; Joseph C Cleveland; Ke-Seng Zhao; David A Fullerton; Xianzhong Meng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-13       Impact factor: 8.311

Review 9.  The 'valvulo-metabolic' risk in calcific aortic valve disease.

Authors:  Patrick Mathieu; J P Després; P Pibarot
Journal:  Can J Cardiol       Date:  2007-10       Impact factor: 5.223

10.  Ex vivo evidence for the contribution of hemodynamic shear stress abnormalities to the early pathogenesis of calcific bicuspid aortic valve disease.

Authors:  Ling Sun; Santanu Chandra; Philippe Sucosky
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.